The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUNDThe current study was a multicenter, single‐arm, phase 2 study performed to investigate the feasibility and efficacy of bevacizumab combined with docetaxel, oxaliplatin, and capecitabine (B‐DOC) in patients with advanced human epidermal growth factor receptor 2 (HER2)‐negative, previously untreated, gastric or gastroesophageal adenocarcinoma.
METHODSTumor HER2 status was determined centrally...
BACKGROUND:The purpose of this study was to compare 2 weekly docetaxel‐based regimens as first‐line treatments for advanced gastric cancer and to investigate the expression of secreted protein acidic and rich in cysteine (SPARC) and its abilities to predict treatment‐related clinical outcomes.
METHODS:Patients were randomly selected to receive 3 weekly cycles of docetaxel (35 mg/m2 on days 1 and...
The docetaxel-cisplatin-5-fluorouracil (TCF) triplet has demonstrated superiority over cisplatin-5-fluorouracil (CF) and subsequently gained approval in the USA and Europe for the treatment of advanced gastric cancer. While this is a major advancementin gastric cancer therapy, there is potential to further improve outcomes by optimizing and building of the TCF regimen. The availability of ‘new’ cytotoxic...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.